Peder Digre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peder Digre has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
Joseph Wagman
3 shared publicationsBaltazar Candrinho
National Malaria Control Programme, Mozambique Minister of Health, Maputo, Mozambique
2 shared publicationsChristelle Gogue
2 shared publicationsJohn Miller
PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia
2 shared publicationsMolly Robertson
The Global Fund to Fight AIDS, Tuberculosis, and Malaria, Geneva, Switzerland
2 shared publications- Tara Herrick
Market Dynamics, PATH , 2201 Westlake Avenue, Suite 200, Seattle, WA 98121
2 shared publications
Latest Publications
- Open Access
- 15 July 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (9) , 101415
Disentangling patterns of community malaria transmission and burden using malaria prevalence among pregnant women attending antenatal care: a modelling study
- 15 July 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (9) , 101415
Open AccessDisentangling patterns of community malaria transmission and burden using malaria prevalence among pregnant women attending antenatal care: a modelling study
- Open Access
- 20 December 2025
- Published by Springer Nature in Parasites & Vectors
- Vol. 19 (1)
Differential effects of dual and synergist-based insecticide-treated bed nets on pyrethroid resistance and L995F/S knockdown resistance mutation dynamics in Anopheles gambiae s.l. populations in south-western Burkina Faso
Background: The introduction of next-generation insecticide-treated nets (ITNs) in Burkina Faso aims to mitigate pyrethroid resistance in malaria vectors. This study evaluated the impact of different ITN types on phenotypic resistance and kdr mutation frequencies in Anopheles gambiae sensus lacto (s.l.) populations across three health districts over 3 years. Methods: Annual mosquito collections were conducted in Banfora (where pyrethroid–chlorfenapyr nets had been distributed), Gaoua (pyrethroid-only ITNs) and Orodara (pyrethroid–piperonyl butoxide [PBO] ITNs). Two populations were analysed: adult females collected directly from the field and those reared from field-collected larvae. World Health Organization (WHO) susceptibility bioassays measured 24-h mortality after exposure to 1×, 5× and 10× concentrations of deltamethrin and alphacypermethrin, with and without pre-exposure to piperonyl butoxide. Frequencies of kdr mutations L995F and L995S were determined by polymerase chain reaction (PCR). Results: High-intensity resistance was observed in each study district, with mortality consistently below 45% and not reaching WHO thresholds even at 10× doses. PBO increased mortality, indicating metabolic resistance, but failed to restore full susceptibility. L995F predominated across all districts, years and mosquito populations. L995S remained low and variable. Pyr-only nets were associated with rising L995F frequencies and lower mortality in resistance assays. Pyrethroid (Pyr)–chlorfenapyr (CFR) nets improved mortality in resistance assays without increasing kdr prevalence. Pyr–PBO nets showed partial and inconsistent efficacy, with mosquitoes having mixed patterns in resistance assays. Similar patterns between field and laboratory-reared populations were observed. Conclusions: ITN type strongly influenced resistance dynamics. Dual-active ingredient (AI) nets, particularly Pyr–CFR, appear more effective in managing resistance. Integrated resistance management combining ITN rotation, routine monitoring and complementary interventions is essential to preserve vector control efficacy. Graphical
- 20 December 2025
- Published by Springer Nature in Parasites & Vectors
- Vol. 19 (1)
Open AccessDifferential effects of dual and synergist-based insecticide-treated bed nets on pyrethroid resistance and L995F/S knockdown resistance mutation dynamics in Anopheles gambiae s.l. populations in south-western Burkina Faso
Background: The introduction of next-generation insecticide-treated nets (ITNs) in Burkina Faso aims to mitigate pyrethroid resistance in malaria vectors. This study evaluated the impact of different ITN types on phenotypic resistance and kdr mutation frequencies in Anopheles gambiae sensus lacto (s.l.) populations across three health districts over 3 years. Methods: Annual mosquito collections were conducted in Banfora (where pyrethroid–chlorfenapyr nets had been distributed), Gaoua (pyrethroid-only ITNs) and Orodara (pyrethroid–piperonyl butoxide [PBO] ITNs). Two populations were analysed: adult females collected directly from the field and those reared from field-collected larvae. World Health Organization (WHO) susceptibility bioassays measured 24-h mortality after exposure to 1×, 5× and 10× concentrations of deltamethrin and alphacypermethrin, with and without pre-exposure to piperonyl butoxide. Frequencies of kdr mutations L995F and L995S were determined by polymerase chain reaction (PCR). Results: High-intensity resistance was observed in each study district, with mortality consistently below 45% and not reaching WHO thresholds even at 10× doses. PBO increased mortality, indicating metabolic resistance, but failed to restore full susceptibility. L995F predominated across all districts, years and mosquito populations. L995S remained low and variable. Pyr-only nets were associated with rising L995F frequencies and lower mortality in resistance assays. Pyrethroid (Pyr)–chlorfenapyr (CFR) nets improved mortality in resistance assays without increasing kdr prevalence. Pyr–PBO nets showed partial and inconsistent efficacy, with mosquitoes having mixed patterns in resistance assays. Similar patterns between field and laboratory-reared populations were observed. Conclusions: ITN type strongly influenced resistance dynamics. Dual-active ingredient (AI) nets, particularly Pyr–CFR, appear more effective in managing resistance. Integrated resistance management combining ITN rotation, routine monitoring and complementary interventions is essential to preserve vector control efficacy. Graphical
- Open Access
- 30 September 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (9) , e018572
Antenatal care surveillance for monitoring malaria prevalence and intervention coverage: a multicountry analysis
Estimates of malaria prevalence and intervention coverage in Africa are primarily based on nationally representative household (HH) surveys. However, the expense and infrequency limit the utility of HH surveys for operational action by malaria programmes. We assessed whether data collected during first antenatal care (ANC1) visits, consisting of data on malaria prevalence using rapid diagnostic tests, ownership of insecticide-treated nets (ITNs) and treatment-seeking for children with fever, could provide relevant data to guide decision-makers. Malaria prevalence among ANC1 attendees in select areas of six countries (Benin, Burkina Faso, Mozambique, Nigeria, Tanzania and Zambia) was compared with prevalence data among children under 5 and school-aged children from cross-sectional HH surveys in the same areas. To examine the relationship between prevalence among ANC1 attendees and children, we fitted a linear trend to the log-OR of the risk of testing positive. The predictive performance of the model was assessed by leave-one-out cross-validation (LOOCV). District-level ANC1 prevalence and prevalence among children are correlated (Spearman’s rank correlation, r=0.79, 95% CI=0.65 to 0.88, p<0.001) and ANC1 prevalence is predictive of prevalence among children (LOOCV mean absolute error=6.5%). To understand whether data on ITN ownership collected at ANC1 are representative of ownership in the underlying communities, we assessed the district-level proportion of HH ownership in five countries (Benin, Burkina Faso, Mozambique, Nigeria and Zambia) and fitted an ordinal regression model to the ranking of ownership by district. Reported rates of treatment-seeking for children under 5 with fever, testing for malaria and treatment for the HH and ANC1 settings were compared. Estimates of malaria prevalence and ITN coverage derived from ANC1 attendees correlate well with HH survey estimates and may be useful in monitoring malaria prevalence and prevention efforts. In contrast, data on treatment-seeking does not appear useful.
- 30 September 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (9) , e018572
Open AccessAntenatal care surveillance for monitoring malaria prevalence and intervention coverage: a multicountry analysis
Estimates of malaria prevalence and intervention coverage in Africa are primarily based on nationally representative household (HH) surveys. However, the expense and infrequency limit the utility of HH surveys for operational action by malaria programmes. We assessed whether data collected during first antenatal care (ANC1) visits, consisting of data on malaria prevalence using rapid diagnostic tests, ownership of insecticide-treated nets (ITNs) and treatment-seeking for children with fever, could provide relevant data to guide decision-makers. Malaria prevalence among ANC1 attendees in select areas of six countries (Benin, Burkina Faso, Mozambique, Nigeria, Tanzania and Zambia) was compared with prevalence data among children under 5 and school-aged children from cross-sectional HH surveys in the same areas. To examine the relationship between prevalence among ANC1 attendees and children, we fitted a linear trend to the log-OR of the risk of testing positive. The predictive performance of the model was assessed by leave-one-out cross-validation (LOOCV). District-level ANC1 prevalence and prevalence among children are correlated (Spearman’s rank correlation, r=0.79, 95% CI=0.65 to 0.88, p<0.001) and ANC1 prevalence is predictive of prevalence among children (LOOCV mean absolute error=6.5%). To understand whether data on ITN ownership collected at ANC1 are representative of ownership in the underlying communities, we assessed the district-level proportion of HH ownership in five countries (Benin, Burkina Faso, Mozambique, Nigeria and Zambia) and fitted an ordinal regression model to the ranking of ownership by district. Reported rates of treatment-seeking for children under 5 with fever, testing for malaria and treatment for the HH and ANC1 settings were compared. Estimates of malaria prevalence and ITN coverage derived from ANC1 attendees correlate well with HH survey estimates and may be useful in monitoring malaria prevalence and prevention efforts. In contrast, data on treatment-seeking does not appear useful.
- Open Access
- 28 November 2024
- Published by Oxford University Press (OUP) in Oxford Open Digital Health
- Vol. 2 (Supplement) , ii1-ii3
Building the evidence base for the economic value of digital health interventions: examples of methods and metrics and opportunities for future directions
: Quantifying the costs, impact and cost-effectiveness of digital health interventions (DHIs) presents both technical and logistical challenges, largely due to unclear causal pathways to health impact and the tendency of DHIs to be implemented as just one component of an intervention. Few publications provide peer-reviewed estimates of these metrics for DHIs, especially in low- and middle-income countries (LMICs). Yet decision-makers need this evidence to make informed decisions and investments about DHIs. The special collection outlined here offers seven practical and diverse examples of how digital health implementers have assessed the costs and impacts of DHIs in LMICs. These examples can serve as building blocks to inform and guide the development of critically needed methodological approaches for measuring the cost, impact and value of DHIs in a standardized way. RESUMEN: Cuantificar los costos, el efecto y la efectividad de costos de las intervenciones digitales de salud (DHI, por sus siglas en inglés) representa desafíos tanto técnicos como logísticos, en gran medida debido a la falta de claridad respecto a las secuencias causales para el efecto sobre la salud y la tendencia de las DHI para implementarse como solo un componente de una intervención. Pocas publicaciones ofrecen estimados con revisión por pares de estas métricas para las DHI, especialmente en países de ingresos bajos y medios (LMIC, por sus siglas en inglés). Pero las personas encargadas de tomar decisiones necesitan esta evidencia para tomar decisiones informadas y hacer inversiones relacionadas con las DHI. La colección especial aquí descrita ofrece siete ejemplos prácticos y diversos sobre cómo los ejecutores de salud digital han evaluado los costos y los efectos de las DHI en LMIC. Estos ejemplos pueden usarse como bloques de construcción para informar y guiar el desarrollo de enfoques metodológicos altamente necesarios para medir el costo, el efecto y el valor de las DHI de manera estandarizada. RESUMO: Quantificar os custos, o impacto e a relação custo-eficácia das intervenções de saúde digitais (ISD) apresenta desafios técnicos e logísticos, em grande parte devido a vias causais pouco claras para o impacto na saúde e à tendência das ISD para serem implementadas como apenas um componente de uma intervenção. Poucas publicações fornecem estimativas revistas por pares destas métricas para as IDS, especialmente nos países de baixo e médio rendimento (PBMR). No entanto, os decisores precisam destas provas para tomar decisões e investimentos informados sobre as ISD. A coleção especial aqui delineada oferece sete exemplos práticos e diversificados de como os implementadores de saúde digital avaliaram os custos e os impactos das ISD nos PBMR. Estes exemplos podem servir como blocos de construção para informar e orientar o desenvolvimento de abordagens metodológicas extremamente necessárias para medir o custo, o impacto e o valor das IDS de forma padronizada. RÉSUMÉ: La quantification des coûts, de l’impact et de la rentabilité des interventions de santé numérique (ISN) présente des défis à la fois techniques et logistiques, en grande partie en raison du manque de clarté sur les causes contribuant aux impacts sur la santé et de la tendance des ISN à être mises en œuvre comme un simple composant d’une intervention. Peu de publications fournissent des estimations évaluées par des pairs de ces mesures pour les ISN, en particulier dans les pays à revenu faible et intermédiaire (PRFI). Pourtant, les décideurs ont besoin de ces preuves pour prendre des décisions éclairées et réaliser des investissements en matière d’ISN. La collection spéciale présentée ici offre sept exemples pratiques et divers de la manière dont les responsables de la mise en œuvre de la santé numérique ont évalué les coûts et les impacts des ISN dans les PRFI. Ces exemples peuvent servir de base pour informer et guider le développement d’approches méthodologiques indispensables pour mesurer le coût, l’impact et la valeur des ISN de manière standardisée.
- 28 November 2024
- Published by Oxford University Press (OUP) in Oxford Open Digital Health
- Vol. 2 (Supplement) , ii1-ii3
Open AccessBuilding the evidence base for the economic value of digital health interventions: examples of methods and metrics and opportunities for future directions
: Quantifying the costs, impact and cost-effectiveness of digital health interventions (DHIs) presents both technical and logistical challenges, largely due to unclear causal pathways to health impact and the tendency of DHIs to be implemented as just one component of an intervention. Few publications provide peer-reviewed estimates of these metrics for DHIs, especially in low- and middle-income countries (LMICs). Yet decision-makers need this evidence to make informed decisions and investments about DHIs. The special collection outlined here offers seven practical and diverse examples of how digital health implementers have assessed the costs and impacts of DHIs in LMICs. These examples can serve as building blocks to inform and guide the development of critically needed methodological approaches for measuring the cost, impact and value of DHIs in a standardized way. RESUMEN: Cuantificar los costos, el efecto y la efectividad de costos de las intervenciones digitales de salud (DHI, por sus siglas en inglés) representa desafíos tanto técnicos como logísticos, en gran medida debido a la falta de claridad respecto a las secuencias causales para el efecto sobre la salud y la tendencia de las DHI para implementarse como solo un componente de una intervención. Pocas publicaciones ofrecen estimados con revisión por pares de estas métricas para las DHI, especialmente en países de ingresos bajos y medios (LMIC, por sus siglas en inglés). Pero las personas encargadas de tomar decisiones necesitan esta evidencia para tomar decisiones informadas y hacer inversiones relacionadas con las DHI. La colección especial aquí descrita ofrece siete ejemplos prácticos y diversos sobre cómo los ejecutores de salud digital han evaluado los costos y los efectos de las DHI en LMIC. Estos ejemplos pueden usarse como bloques de construcción para informar y guiar el desarrollo de enfoques metodológicos altamente necesarios para medir el costo, el efecto y el valor de las DHI de manera estandarizada. RESUMO: Quantificar os custos, o impacto e a relação custo-eficácia das intervenções de saúde digitais (ISD) apresenta desafios técnicos e logísticos, em grande parte devido a vias causais pouco claras para o impacto na saúde e à tendência das ISD para serem implementadas como apenas um componente de uma intervenção. Poucas publicações fornecem estimativas revistas por pares destas métricas para as IDS, especialmente nos países de baixo e médio rendimento (PBMR). No entanto, os decisores precisam destas provas para tomar decisões e investimentos informados sobre as ISD. A coleção especial aqui delineada oferece sete exemplos práticos e diversificados de como os implementadores de saúde digital avaliaram os custos e os impactos das ISD nos PBMR. Estes exemplos podem servir como blocos de construção para informar e orientar o desenvolvimento de abordagens metodológicas extremamente necessárias para medir o custo, o impacto e o valor das IDS de forma padronizada. RÉSUMÉ: La quantification des coûts, de l’impact et de la rentabilité des interventions de santé numérique (ISN) présente des défis à la fois techniques et logistiques, en grande partie en raison du manque de clarté sur les causes contribuant aux impacts sur la santé et de la tendance des ISN à être mises en œuvre comme un simple composant d’une intervention. Peu de publications fournissent des estimations évaluées par des pairs de ces mesures pour les ISN, en particulier dans les pays à revenu faible et intermédiaire (PRFI). Pourtant, les décideurs ont besoin de ces preuves pour prendre des décisions éclairées et réaliser des investissements en matière d’ISN. La collection spéciale présentée ici offre sept exemples pratiques et divers de la manière dont les responsables de la mise en œuvre de la santé numérique ont évalué les coûts et les impacts des ISN dans les PRFI. Ces exemples peuvent servir de base pour informer et guider le développement d’approches méthodologiques indispensables pour mesurer le coût, l’impact et la valeur des ISN de manière standardisée.
- Open Access
- 11 June 2022
- Published by Springer Nature in Malaria Journal
- Vol. 21 (1) , 1-15
Incremental cost and cost-effectiveness of the addition of indoor residual spraying with pirimiphos-methyl in sub-Saharan Africa versus standard malaria control: results of data collection and analysis in the Next Generation Indoor Residual Sprays (NgenIRS) project, an economic-evaluation
Background: Malaria is a major cause of morbidity and mortality globally, especially in sub-Saharan Africa. Widespread resistance to pyrethroids threatens the gains achieved by vector control. To counter resistance to pyrethroids, third-generation indoor residual spraying (3GIRS) products have been developed. This study details the results of a multi-country cost and cost-effectiveness analysis of indoor residual spraying (IRS) programmes using Actellic®300CS, a 3GIRS product with pirimiphos-methyl, in sub-Saharan Africa in 2017 added to standard malaria control interventions including insecticide-treated bed nets versus standard malaria control interventions alone. Methods: An economic evaluation of 3GIRS using Actellic®300CS in a broad range of sub-Saharan African settings was conducted using a variety of primary data collection and evidence synthesis methods. Four IRS programmes in Ghana, Mali, Uganda, and Zambia were included in the effectiveness analysis. Cost data come from six IRS programmes: one in each of the four countries where effect was measured plus Mozambique and a separate programme conducted by AngloGold Ashanti Malaria Control in Ghana. Financial and economic costs were quantified and valued. The main indicator for the cost was cost per person targeted. Country-specific case incidence rate ratios (IRRs), estimated by comparing IRS study districts to adjacent non-IRS study districts or facilities, were used to calculate cases averted in each study area. A deterministic analysis and sensitivity analysis were conducted in each of the four countries for which effectiveness evaluations were available. Probabilistic sensitivity analysis was used to generate plausibility bounds around the incremental cost-effectiveness ratio estimates for adding IRS to other standard interventions in each study setting as well as jointly utilizing data on effect and cost across all settings. Results: Overall, IRRs from each country indicated that adding IRS with Actellic®300CS to the local standard intervention package was protective compared to the standard intervention package alone (IRR 0.67, [95% CI 0.50–0.91]). Results indicate that Actellic®300CS is expected to be a cost-effective (> 60% probability of being cost-effective in all settings) or highly cost-effective intervention across a range of transmission settings in sub-Saharan Africa. Discussion: Variations in the incremental costs and cost-effectiveness likely result from several sources including: variation in the sprayed wall surfaces and house size relative to household population, the underlying malaria burden in the communities sprayed, the effectiveness of 3GIRS in different settings, and insecticide price. Programmes should be aware that current recommendations to rotate can mean variation and uncertainty in budgets; programmes should consider this in their insecticide-resistance management strategies. Conclusions: The optimal combination of 3GIRS delivery with other malaria control interventions will be highly context specific. 3GIRS using Actellic®300CS is expected to deliver acceptable value for money in a broad range of sub-Saharan African malaria transmission settings.
- 11 June 2022
- Published by Springer Nature in Malaria Journal
- Vol. 21 (1) , 1-15
Open AccessIncremental cost and cost-effectiveness of the addition of indoor residual spraying with pirimiphos-methyl in sub-Saharan Africa versus standard malaria control: results of data collection and analysis in the Next Generation Indoor Residual Sprays (NgenIRS) project, an economic-evaluation
Background: Malaria is a major cause of morbidity and mortality globally, especially in sub-Saharan Africa. Widespread resistance to pyrethroids threatens the gains achieved by vector control. To counter resistance to pyrethroids, third-generation indoor residual spraying (3GIRS) products have been developed. This study details the results of a multi-country cost and cost-effectiveness analysis of indoor residual spraying (IRS) programmes using Actellic®300CS, a 3GIRS product with pirimiphos-methyl, in sub-Saharan Africa in 2017 added to standard malaria control interventions including insecticide-treated bed nets versus standard malaria control interventions alone. Methods: An economic evaluation of 3GIRS using Actellic®300CS in a broad range of sub-Saharan African settings was conducted using a variety of primary data collection and evidence synthesis methods. Four IRS programmes in Ghana, Mali, Uganda, and Zambia were included in the effectiveness analysis. Cost data come from six IRS programmes: one in each of the four countries where effect was measured plus Mozambique and a separate programme conducted by AngloGold Ashanti Malaria Control in Ghana. Financial and economic costs were quantified and valued. The main indicator for the cost was cost per person targeted. Country-specific case incidence rate ratios (IRRs), estimated by comparing IRS study districts to adjacent non-IRS study districts or facilities, were used to calculate cases averted in each study area. A deterministic analysis and sensitivity analysis were conducted in each of the four countries for which effectiveness evaluations were available. Probabilistic sensitivity analysis was used to generate plausibility bounds around the incremental cost-effectiveness ratio estimates for adding IRS to other standard interventions in each study setting as well as jointly utilizing data on effect and cost across all settings. Results: Overall, IRRs from each country indicated that adding IRS with Actellic®300CS to the local standard intervention package was protective compared to the standard intervention package alone (IRR 0.67, [95% CI 0.50–0.91]). Results indicate that Actellic®300CS is expected to be a cost-effective (> 60% probability of being cost-effective in all settings) or highly cost-effective intervention across a range of transmission settings in sub-Saharan Africa. Discussion: Variations in the incremental costs and cost-effectiveness likely result from several sources including: variation in the sprayed wall surfaces and house size relative to household population, the underlying malaria burden in the communities sprayed, the effectiveness of 3GIRS in different settings, and insecticide price. Programmes should be aware that current recommendations to rotate can mean variation and uncertainty in budgets; programmes should consider this in their insecticide-resistance management strategies. Conclusions: The optimal combination of 3GIRS delivery with other malaria control interventions will be highly context specific. 3GIRS using Actellic®300CS is expected to deliver acceptable value for money in a broad range of sub-Saharan African malaria transmission settings.
- Open Access
- 12 July 2017
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 15 (1) , 12
Modeling the potential impact of emerging innovations on achievement of Sustainable Development Goals related to maternal, newborn, and child health
Innovations that improve the affordability, accessibility, or effectiveness of health care played a major role in the Millennium Development Goal achievements and will be critical for reaching the ambitious new Sustainable Development Goal (SDG) health targets. Mechanisms to identify and prioritize innovations are essential to inform future investment decisions. Innovation Countdown 2030 crowdsourced health innovations from around the world and engaged recognized experts to systematically assess their lifesaving potential by 2030. A health impact modeling approach was developed and used to quantify the costs and lives saved for select innovations identified as having great promise for improving maternal, newborn, and child health. Preventive innovations targeting health conditions with a high mortality burden had the greatest impact in regard to the absolute number of estimated lives saved. The largest projected health impact was for a new tool for small-scale water treatment that automatically chlorinates water to a safe concentration without using electricity or moving parts. An estimated 1.5 million deaths from diarrheal disease among children under five could be prevented by 2030 by scaling up use of this technology. Use of chlorhexidine for umbilical cord care was associated with the second highest number of lives saved. The results show why a systematic modeling approach that can compare and contrast investment opportunities is important for prioritizing global health innovations. Rigorous impact estimates are needed to allocate limited resources toward the innovations with great potential to advance the SDGs.
- 12 July 2017
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 15 (1) , 12
Open AccessModeling the potential impact of emerging innovations on achievement of Sustainable Development Goals related to maternal, newborn, and child health
Innovations that improve the affordability, accessibility, or effectiveness of health care played a major role in the Millennium Development Goal achievements and will be critical for reaching the ambitious new Sustainable Development Goal (SDG) health targets. Mechanisms to identify and prioritize innovations are essential to inform future investment decisions. Innovation Countdown 2030 crowdsourced health innovations from around the world and engaged recognized experts to systematically assess their lifesaving potential by 2030. A health impact modeling approach was developed and used to quantify the costs and lives saved for select innovations identified as having great promise for improving maternal, newborn, and child health. Preventive innovations targeting health conditions with a high mortality burden had the greatest impact in regard to the absolute number of estimated lives saved. The largest projected health impact was for a new tool for small-scale water treatment that automatically chlorinates water to a safe concentration without using electricity or moving parts. An estimated 1.5 million deaths from diarrheal disease among children under five could be prevented by 2030 by scaling up use of this technology. Use of chlorhexidine for umbilical cord care was associated with the second highest number of lives saved. The results show why a systematic modeling approach that can compare and contrast investment opportunities is important for prioritizing global health innovations. Rigorous impact estimates are needed to allocate limited resources toward the innovations with great potential to advance the SDGs.
- Open Access
- 16 September 2016
- Published by International Society of Global Health in Journal of Global Health
- Vol. 6 (2) , 020407
Caregiver perceptions and utilization of oral rehydration solution and other treatments for diarrhea among young children in Burkina Faso
More than 500 000 young children die from dehydration caused by severe diarrhea each year, globally. Although routine use of oral rehydration solution (ORS) could prevent almost all of these deaths, ORS utilization remains low in many low-income countries. Previous research has suggested that misperceptions among caregivers may be an obstacle to wider use of ORS. To better understand the extent of ORS utilization and the reasons for use or non-use in low-resource settings, the project team conducted a semi-structured, quantitative survey of 400 caregivers in Burkina Faso in 2014. All caregivers had a child below the age of five who had diarrhea lasting 2 days or more in the previous 2 months. Although more than 80% of caregivers were aware of ORS, less than half reported using it to treat their child's diarrhea. Replacing fluids lost due to diarrhea was considered a low priority by most caregivers, and many said they considered antibiotics more effective for treating diarrhea. Users and non-users of ORS held substantially different perceptions of the product, though all caregivers tended to follow recommendations of health care workers. A significant proportion of users reported difficulty in getting a child to drink ORS. Costs and access to ORS were not found to be significant barriers to use. Misperceptions among caregivers and health workers contribute to low utilization of ORS. Better caregiver understanding of diarrheal disease and the importance of rehydration, as well as increased recommendation by health workers, will help to increase ORS utilization. Improving product presentation and taste will also help to increase use.
- 16 September 2016
- Published by International Society of Global Health in Journal of Global Health
- Vol. 6 (2) , 020407
Open AccessCaregiver perceptions and utilization of oral rehydration solution and other treatments for diarrhea among young children in Burkina Faso
More than 500 000 young children die from dehydration caused by severe diarrhea each year, globally. Although routine use of oral rehydration solution (ORS) could prevent almost all of these deaths, ORS utilization remains low in many low-income countries. Previous research has suggested that misperceptions among caregivers may be an obstacle to wider use of ORS. To better understand the extent of ORS utilization and the reasons for use or non-use in low-resource settings, the project team conducted a semi-structured, quantitative survey of 400 caregivers in Burkina Faso in 2014. All caregivers had a child below the age of five who had diarrhea lasting 2 days or more in the previous 2 months. Although more than 80% of caregivers were aware of ORS, less than half reported using it to treat their child's diarrhea. Replacing fluids lost due to diarrhea was considered a low priority by most caregivers, and many said they considered antibiotics more effective for treating diarrhea. Users and non-users of ORS held substantially different perceptions of the product, though all caregivers tended to follow recommendations of health care workers. A significant proportion of users reported difficulty in getting a child to drink ORS. Costs and access to ORS were not found to be significant barriers to use. Misperceptions among caregivers and health workers contribute to low utilization of ORS. Better caregiver understanding of diarrheal disease and the importance of rehydration, as well as increased recommendation by health workers, will help to increase ORS utilization. Improving product presentation and taste will also help to increase use.